Analyst consensus on AVXL stock forecast remains split — bulls highlight regulatory catalysts, bears note cash burn rate — creating choppy market conditions for swing traders. We can see that Anavex Life Sciences does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Anavex Life Sciences' earnings history below. Of course, the future is what really matters. Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report AVXL stock forecast models from equity research desks use scenario planning; baseline target sits at $10.84, while optimistic projections reach $14 if Phase 3 endpoints show statistically significant results.